Sign inJoin waitlistJoin the waitlist

Shivaani Kummar

Director, Knight Cancer Institute · Oregon Health & Science University

Credentials: · · · · · ·

History

Knight Cancer Institute Center · Oregon Health & Science University
Present
OHSU Knight Cancer Institute Center · Oregon Health & Science University
Present
Medicine Department · Oregon Health & Science University
Present

Research

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
New England Journal of Medicine · 2018 · 2,193 citations
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
The Lancet Oncology · 2020 · 835 citations
Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer
Cancer Discovery · 2020 · 289 citations

James Doroshow
81 papers
AC
Alice Chen
52 papers
Martin Gutierrez
25 papers
KD
Khanh Do
19 papers · 1 as a fellow
LJ
Lamin Juwara
17 papers
RP
Richard Piekarz
15 papers
William Figg
14 papers
GC
Geraldine Coyne
13 papers · 1 as a fellow
Peter Choyke
13 papers
NT
Naoko Takebe
11 papers
Barbara Conley
10 papers
GG
Giuseppe Giaccone
10 papers

Grants

Experimental Therapeutics in Cancer Training Program
National Cancer Institute · T32
Contact PI · $449.6K · Oregon Health & Science University
2025–2029
OHSU Knight Cancer Institute
National Cancer Institute · P30
Contact PI · $7.3M · Oregon Health & Science University
1997–2027
[18F]-AraG -PET Imaging to Evaluate Immunological Response to Checkpoint Inhibitor Therapy (CKI) in Patients with Advanced Solid Tumors
National Cancer Institute · R01
Contact PI · $999.1K · Oregon Health & Science University
2020–2026
PQ3: Age-Related Immune Deviation and Cancer Outcome
National Cancer Institute · R21
PI · $378K · Stanford University
2016–2019

Clinical trials

Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors
Principal investigator · Recruiting · Phase 1, Phase 2
OHSU Knight Cancer Institute
2024–2029
A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors
Principal investigator · Terminated · Phase 2
CellSight Technologies, Inc.
2022–2026
GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy
Principal investigator · Completed · Phase 1
Genome & Company
2020–2023
Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.
Principal investigator · Completed · Phase 1, Phase 2
Mundipharma Research Limited
2017–2023